Hanne Kristin Fredly's picture
Hanne Kristin
Fredly
PhD Candidate
Visit Address: 
Haukeland universitetssykehus, Laboratoriebygget
5021 Bergen
Postal Address: 
Postboks 7804
5021 Bergen
E-mail: 
Hanne.Fredly@k2.uib.no
Download vCard
Journal articles
  • Haaland, Ingvild; Opsahl, Jill Anette; Berven, Frode; Reikvam, Håkon; Fredly, Hanne Kristin; Haugse, Ragnhild; Thiede, Bernd; McCormack, Emmet; Lain, Sonia; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2014. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Molecular Cancer. 13. doi: 10.1186/1476-4598-13-116
  • Astori, Audrey; Fredly, Hanne Kristin; Aloysius, Thomas Aquinas; Bullinger, Lars; Mansat-De Mas, Véronique; de la Grange, Pierre; Delhommeau, François; Hagen, Karen Marie; Récher, Christian; Dusanter-Fourt, Isabelle; Knappskog, Stian; Lillehaug, Johan R.; Pendino, Frederic; Bruserud, Øystein. 2013. CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia. OncoTarget. 4: 1438-1448.
  • Fredly, Hanne Kristin; Ersvær, Elisabeth; Kittang, Astrid Marta Olsnes; Tsykunova, Galina; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2013. The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clinical Epigenetics. 5:13. doi: 10.1186/1868-7083-5-13
  • Fredly, Hanne Kristin; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2013. Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clinical Epigenetics. 5:12. doi: 10.1186/1868-7083-5-12
  • Reikvam, Håkon; Fredly, Hanne Kristin; Kittang, Astrid Marta Olsnes; Bruserud, Øystein. 2013. The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine-the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation. Toxins. 5: 336-362. doi: 10.3390/toxins5020336
  • Fredly, Hanne Kristin; Reikvam, Håkon; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2012. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. American Journal of Hematology. 87: 368-376. doi: 10.1002/ajh.23116
  • Reikvam, Håkon; Hatfield, Kimberley Joanne; Fredly, Hanne Kristin; Nepstad, Ina; Mosevoll, Knut Anders; Bruserud, Øystein. 2012. The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation. European Cytokine Network. 23: 140-153. doi: 10.1684/ecn.2012.0322
  • Fredly, Hanne Kristin; Ersvær, Elisabeth; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2011. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncology Reports. 25: 1549-1556. doi: 10.3892/or.2011.1229
  • Fredly, Hanne Kristin; Bjørnsen, Camilla I. Stapnes; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2010. Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia - a report of five cases. Hematology. 15: 338-343. doi: 10.1179/102453310X12647083620967
  • Fredly, Hanne Kristin; Ersvær, Elisabeth; Bruserud, Øystein. 2010. PRIMARY HUMAN ACUTE MYELOGENOUS LEUKEMIA CELLS RELEASE HEAT SHOCK PROTEIN (HSP) 70 AND HSP90 DURING APOPTOSIS. Experimental Hematology. 38: S19-S20.
  • Fredly, Hanne Kristin; Ersvær, Elisabeth; Bruserud, Øystein. 2010. PRIMARY HUMAN AML CELLS CAN EXPRESS CALRETICULIN ON THE CELL SURFACE AND RELEASE HEAT SHOCK PROTEIN 70 (HSP70) AND HSP90 DURING APOPTOSIS. Haematologica. 95: 496-497.
Reports and theses
  • Fredly, Hanne Kristin. 2013. Disease-stabilizing treatment of human acute myeloid leukaemia – experimental and clinical studies. University of Bergen.

More information in national current research information system (CRIStin)